Chong-Xian Pan

Title(s)Adjunct Professor, Hematology and Oncology
SchoolUniversity of California, Davis
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
    NIH I01CX002247Oct 1, 2020 - Sep 30, 2024
    Role: Principal Investigator
    University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities
    NIH U54CA233306Sep 1, 2018 - Jun 30, 2023
    Role: Co-Principal Investigator
    Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
    NIH I01BX003840Apr 1, 2018 - Mar 31, 2022
    Role: Principal Investigator
    Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
    NIH R01CA176803Apr 15, 2015 - Mar 31, 2021
    Role: Principal Investigator
    Development of targeting nanotherapeutics against bladder cancer
    NIH I01BX001784Oct 1, 2013 - Sep 30, 2017
    Role: Principal Investigator
    UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program
    NIH K12CA138464Jan 1, 2009 - Jul 31, 2026
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. J Clin Invest. 2021 11 15; 131(22). Bekele RT, Samant AS, Nassar AH, So J, Garcia EP, Curran CR, Hwang JH, Mayhew DL, Nag A, Thorner AR, Börcsök J, Sztupinszki Z, Pan CX, Bellmunt J, Kwiatkowski DJ, Sonpavde GP, Van Allen EM, Mouw KW. PMID: 34554931; PMCID: PMC8592548.
      View in: PubMed   Mentions:
    2. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. J Immunother Cancer. 2021 11; 9(11). Zhu S, Ma AH, Zhu Z, Adib E, Rao T, Li N, Ni K, Chittepu VCSR, Prabhala R, Garisto Risco J, Kwiatkowski D, Mouw K, Sonpavde G, Cheng F, Pan CX. PMID: 34725212; PMCID: PMC8562536.
      View in: PubMed   Mentions:
    3. Preclinical Models for Bladder Cancer Research. Hematol Oncol Clin North Am. 2021 Jun; 35(3):613-632. Zhu S, Zhu Z, Ma AH, Sonpavde GP, Cheng F, Pan CX. PMID: 33958154.
      View in: PubMed   Mentions:    Fields:    
    4. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Sci Rep. 2021 03 18; 11(1):6377. Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. PMID: 33737681.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    5. Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. Cancer Lett. 2021 04 28; 504:49-57. Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ, Platero AJ, Ma AH, Pan CX, Ghosh PM, Mudryj M. PMID: 33549708.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun. 2020 09 14; 11(1):4591. Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin TY, Pan CX, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, Monjazeb AM, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ. PMID: 32929084.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    7. Cytotoxic and chemosensitizing effects of glycoalkaloidic extract on 2D and 3D models using RT4 and patient derived xenografts bladder cancer cells. Mater Sci Eng C Mater Biol Appl. 2021 Feb; 119:111460. Miranda MA, Marcato PD, Mondal A, Chowdhury N, Gebeyehu A, Surapaneni SK, Bentley MVLB, Amaral R, Pan CX, Singh M. PMID: 33321591.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    8. Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration-resistant prostate cancer. Adv Ther (Weinh). 2020 Oct; 3(10). Huang Y, Xue X, Li X, Jia B, Pan CX, Li Y, Lin TY. PMID: 33072858.
      View in: PubMed   Mentions:
    9. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. Cancer Immunol Immunother. 2020 Nov; 69(11):2305-2317. Long Q, Ma AH, Zhang H, Cao Z, Xia R, Lin TY, Sonpavde GP, de Vere White R, Guo J, Pan CX. PMID: 32506263.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    10. A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models. Cancers (Basel). 2020 May 21; 12(5). Amaral R, Zimmermann M, Ma AH, Zhang H, Swiech K, Pan CX. PMID: 32455634.
      View in: PubMed   Mentions: 3  
    11. Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. Mol Cancer Ther. 2020 04; 19(4):1070-1079. Zimmermann M, Li T, Semrad TJ, Wu CY, Yu A, Cimino G, Malfatti M, Haack K, Turteltaub KW, Pan CX, Cho M, Kim EJ, Henderson PT. PMID: 32029633.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    12. Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. Int J Mol Sci. 2019 Oct 09; 20(20). Martin KA, Hum NR, Sebastian A, He W, Siddiqui S, Ghosh PM, Pan CX, de Vere White R, Loots GG. PMID: 31600961.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    13. Fidelity of a PDX-CR model for bladder cancer. Biochem Biophys Res Commun. 2019 09 10; 517(1):49-56. Mondal AM, Ma AH, Li G, Krawczyk E, Yuan R, Lu J, Schlegel R, Stamatakis L, Kowalczyk KJ, Philips GK, Pan CX, Liu X. PMID: 31303270.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    14. Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. Toxics. 2019 May 09; 7(2). Malfatti MA, Buchholz BA, Enright HA, Stewart BJ, Ognibene TJ, McCartt AD, Loots GG, Zimmermann M, Scharadin TM, Cimino GD, Jonas BA, Pan CX, Bench G, Henderson PT, Turteltaub KW. PMID: 31075884.
      View in: PubMed   Mentions: 1  
    15. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine. 2019 08; 20:102004. Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. PMID: 31055076.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    16. Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel. Chem Res Toxicol. 2018 12 17; 31(12):1293-1304. Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT. PMID: 30381944.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    17. A polymer-free, biomimicry drug self-delivery system fabricated via a synergistic combination of bottom-up and top-down approaches. J Mater Chem B. 2018 12 21; 6(47):7842-7853. Xu X, Yang G, Xue X, Lu H, Wu H, Huang Y, Jing D, Xiao W, Tian J, Yao W, Pan CX, Lin TY, Li Y. PMID: 31380107.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    18. Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. Chem Res Toxicol. 2018 10 15; 31(10):1042-1051. Scharadin TM, Malfatti MA, Haack K, Turteltaub KW, Pan CX, Henderson PT, Jonas BA. PMID: 30152692.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    19. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. Clin Genitourin Cancer. 2018 12; 16(6):421-428.e1. Parikh M, Pan CX, Beckett LA, Li Y, Robles DA, Aujla PK, Lara PN. PMID: 30166228.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    20. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine. 2018 04; 14(3):789-799. Long Q, Lin TY, Huang Y, Li X, Ma AH, Zhang H, Carney R, Airhart S, Lam KS, deVere White RW, Pan CX, Li Y. PMID: 29317342.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    21. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018 03; 32(3):1537-1549. Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG. PMID: 29146734.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansAnimalsCells
    22. Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum. Methods Mol Biol. 2018; 1655:319-334. D'Abronzo LS, Pan CX, Ghosh PM. PMID: 28889394.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther. 2018 02; 17(2):474-483. Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX. PMID: 29284644.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    24. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol. 2017; 2017. Lara PN, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. PMID: 29629426.
      View in: PubMed   Mentions: 4  
    25. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Sci Rep. 2017 09 25; 7(1):12277. Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A. PMID: 28947782.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    26. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017 Nov 18; 390(10109):2266-2277. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T, RANGE study investigators . PMID: 28916371.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    27. The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res. 2017 Nov 01; 23(21):6580-6591. Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX. PMID: 28808038.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    28. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. Int J Cancer. 2017 08 01; 141(3):604-613. Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT. PMID: 28437852.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    29. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 08; 16(8):1521-1530. Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. PMID: 28500234.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    30. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. . 2017 02; 16(2):376-387. Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. PMID: 27903751.
      View in: PubMed   Mentions: 15  Translation:HumansAnimalsCells
    31. Diagnostic Microdosing Approach to Study Gemcitabine Resistance. Chem Res Toxicol. 2016 11 21; 29(11):1843-1848. Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson PT. PMID: 27657672.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    32. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. PMID: 27640312.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    33. Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy. Int J Oncol. 2016 Nov; 49(5):1911-1920. Yi X, Zhang J, Yan F, Lu Z, Huang J, Pan C, Yuan J, Zheng W, Zhang K, Wei D, He W, Yuan J, Yi X, Zhang J, Yan F, Lu Z, Huang J, Pan C, Yuan J, Zheng W, Zhang K, Wei D, He W, Yuan J. PMID: 27633959.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    34. Lipid Cross-Linking of Nanolipoprotein Particles Substantially Enhances Serum Stability and Cellular Uptake. ACS Appl Mater Interfaces. 2016 Aug 17; 8(32):20549-57. Gilmore SF, Blanchette CD, Scharadin TM, Hura GL, Rasley A, Corzett M, Pan CX, Fischer NO, Henderson PT, Gilmore SF, Blanchette CD, Scharadin TM, Hura GL, Rasley A, Corzett M, Pan CX, Fischer NO, Henderson PT. PMID: 27411034.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    35. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer. Biomaterials. 2016 10; 104:339-51. Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX, Lin TY, Li Y, Liu Q, Chen JL, Zhang H, Lac D, Zhang H, Ferrara KW, Wachsmann-Hogiu S, Li T, Airhart S, deVere White R, Lam KS, Pan CX. PMID: 27479049; PMCID: PMC5412594.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    36. HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. Theranostics. 2016; 6(9):1324-35. Lin TY, Guo W, Long Q, Ma A, Liu Q, Zhang H, Huang Y, Chandrasekaran S, Pan C, Lam KS, Li Y, Lin TY, Guo W, Long Q, Ma A, Liu Q, Zhang H, Huang Y, Chandrasekaran S, Pan C, Lam KS, Li Y. PMID: 27375782; PMCID: PMC4924502.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    37. Determinants of Survival for Adolescents and Young Adults with Urothelial Bladder Cancer: Results from the California Cancer Registry. J Urol. 2016 11; 196(5):1378-1382. Lara J, Brunson A, Keegan TH, Malogolowkin M, Pan CX, Yap S, deVere White R, Lara J, Brunson A, Keegan TH, Malogolowkin M, Pan CX, Yap S, deVere White R. PMID: 27208515; PMCID: PMC5319865.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    38. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX, Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. PMID: 27019001; PMCID: PMC4892938.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    39. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 05 01; 34(13):1500-9. Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN, Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. PMID: 26926681.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    40. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS One. 2016; 11(1):e0146256. Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT, Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT. PMID: 26799320; PMCID: PMC4723083.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    41. Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity. Chem Res Toxicol. 2015 Dec 21; 28(12):2250-2. Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, Turteltaub K, Henderson PT, Pan CX, Jiang S, Pan AW, Lin TY, Zhang H, Malfatti M, Turteltaub K, Henderson PT, Pan CX. PMID: 26544157; PMCID: PMC4834887.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    42. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW, Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. PMID: 26270481; PMCID: PMC4535951.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    43. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET, Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. PMID: 25838158; PMCID: PMC4586173.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    44. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN, Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. PMID: 25739672; PMCID: PMC4452427.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    45. Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2015 Jun; 18(2):144-8. Lo EN, Beckett LA, Pan CX, Robles D, Suga JM, Sands JM, Lara PN, Lo EN, Beckett LA, Pan CX, Robles D, Suga JM, Sands JM, Lara PN. PMID: 25667107; PMCID: PMC4430382.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine (Lond). 2015; 10(7):1189-201. Tomlinson B, Lin TY, Dall'Era M, Pan CX, Tomlinson B, Lin TY, Dall'Era M, Pan CX. PMID: 25929573; PMCID: PMC4562431.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    47. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun. 2014 Aug 26; 5:4712. Li Y, Lin TY, Luo Y, Liu Q, Xiao W, Guo W, Lac D, Zhang H, Feng C, Wachsmann-Hogiu S, Walton JH, Cherry SR, Rowland DJ, Kukis D, Pan C, Lam KS, Li Y, Lin TY, Luo Y, Liu Q, Xiao W, Guo W, Lac D, Zhang H, Feng C, Wachsmann-Hogiu S, Walton JH, Cherry SR, Rowland DJ, Kukis D, Pan C, Lam KS. PMID: 25158161; PMCID: PMC4145614.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimalsCells
    48. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS One. 2014; 9(8):e105326. Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R, Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. PMID: 25148033; PMCID: PMC4141800.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    49. Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine (Lond). 2014; 9(12):1807-20. Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX, Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX. PMID: 24628688; PMCID: PMC4167557.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    50. Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer Registry. Urology. 2013 Oct; 82(4):840-5. Pai A, Brunson A, Brown M, Pan CX, Lara PN, Pai A, Brunson A, Brown M, Pan CX, Lara PN. PMID: 24074980.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    51. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis. 2013 Feb; 5(3):369-91. Cimino GD, Pan CX, Henderson PT, Cimino GD, Pan CX, Henderson PT. PMID: 23394702; PMCID: PMC3644565.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    52. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer. Nanomedicine (Lond). 2013 Aug; 8(8):1239-51. Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, White Rde V, Lam KS, Pan CX, Lin TY, Li YP, Zhang H, Luo J, Goodwin N, Gao T, White Rde V, Lam KS, Pan CX. PMID: 23199207; PMCID: PMC3664656.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    53. Contemporary management of muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2012 Jul; 12(7):941-50. Dall'Era MA, Cheng L, Pan CX, Dall'Era MA, Cheng L, Pan CX. PMID: 22845409; PMCID: PMC3494992.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    54. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomedicine. 2012; 7:2793-804. Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, de Vere White R, Lam KS, Pan CX, Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, de Vere White R, Lam KS, Pan CX. PMID: 22745542; PMCID: PMC3383352.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    55. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. Clin Genitourin Cancer. 2012 Jun; 10(2):93-8. Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara PN, Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara PN. PMID: 22382008.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    56. Progress in personalizing chemotherapy for bladder cancer. Adv Urol. 2012; 2012:364919. Chang JS, Lara PN, Pan CX, Chang JS, Lara PN, Pan CX. PMID: 22400017; PMCID: PMC3287014.
      View in: PubMed   Mentions: 10  
    57. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine. 2012 Oct; 8(7):1116-24. Zhang H, Luo J, Li Y, Henderson PT, Wang Y, Wachsmann-Hogiu S, Zhao W, Lam KS, Pan CX, Zhang H, Luo J, Li Y, Henderson PT, Wang Y, Wachsmann-Hogiu S, Zhao W, Lam KS, Pan CX. PMID: 22197725; PMCID: PMC4577023.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    58. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer. 2012 Jun 01; 130(11):2526-38. Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW, Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW. PMID: 21702042; PMCID: PMC4568996.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    59. Current treatment of metastatic bladder cancer and future directions. Expert Rev Anticancer Ther. 2011 Dec; 11(12):1851-62. Lei AQ, Cheng L, Pan CX, Lei AQ, Cheng L, Pan CX. PMID: 22117153.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    60. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct; 30(5):2001-7. Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN, Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN. PMID: 22015991; PMCID: PMC4131984.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    61. The clinical and therapeutic implications of cancer stem cell biology. Expert Rev Anticancer Ther. 2011 Jul; 11(7):1131-43. Cheng L, Alexander R, Zhang S, Pan CX, MacLennan GT, Lopez-Beltran A, Montironi R, Cheng L, Alexander R, Zhang S, Pan CX, MacLennan GT, Lopez-Beltran A, Montironi R. PMID: 21806335.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    62. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol. 2011 Apr; 7(4):519-41. Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M, Montironi R, Lopez-Beltran A, Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M, Montironi R, Lopez-Beltran A. PMID: 21463141.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    63. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN, Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN. PMID: 21431345.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    64. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15; 129(6):1425-34. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX, Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. PMID: 21128223; PMCID: PMC3145006.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    65. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer. 2011 Jan 27; 10(1):9. Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO, de Vere White R, Pan CX, Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO, de Vere White R, Pan CX. PMID: 21272294; PMCID: PMC3040722.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    66. Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. Anticancer Res. 2010 Nov; 30(11):4573-8. Wang S, Zhang H, Cheng L, Evans C, Pan CX, Wang S, Zhang H, Cheng L, Evans C, Pan CX. PMID: 21115908; PMCID: PMC4562399.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    67. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15; 23(11):1653-5. Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN, Turteltaub K, Henderson P, Pan CX, Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN, Turteltaub K, Henderson P, Pan CX. PMID: 21028869; PMCID: PMC2987236.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    68. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX, Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. PMID: 20888272; PMCID: PMC4572726.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    69. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer. 2010 Jun 01; 116(11):2596-603. Sandhu R, Pan CX, Wun T, Harvey D, Zhou H, White RH, Chew HK, Sandhu R, Pan CX, Wun T, Harvey D, Zhou H, White RH, Chew HK. PMID: 20336780.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    70. Human microdosing for the prediction of patient response. Bioanalysis. 2010 Mar; 2(3):373-6. Henderson PT, Pan CX, Henderson PT, Pan CX. PMID: 21083245; PMCID: PMC3113695.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    71. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01; 27(34):5788-93. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D, Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. PMID: 19884559; PMCID: PMC2793000.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    72. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008 Nov 27; 27(56):7106-17. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM, Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. PMID: 18776922; PMCID: PMC2694040.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    73. Rainbow beads: a color coding method to facilitate high-throughput screening and optimization of one-bead one-compound combinatorial libraries. J Comb Chem. 2008 Jul-Aug; 10(4):599-604. Luo J, Zhang H, Xiao W, Kumaresan PR, Shi C, Pan CX, Aina OH, Lam KS, Luo J, Zhang H, Xiao W, Kumaresan PR, Shi C, Pan CX, Aina OH, Lam KS. PMID: 18558750.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    74. Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. Mod Pathol. 2008 Mar; 21(3):355-62. Abbosh PH, Wang M, Eble JN, Lopez-Beltran A, Maclennan GT, Montironi R, Zheng S, Pan CX, Zhou H, Cheng L, Abbosh PH, Wang M, Eble JN, Lopez-Beltran A, Maclennan GT, Montironi R, Zheng S, Pan CX, Zhou H, Cheng L. PMID: 18192966.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    75. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN, Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. PMID: 18272025.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    76. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res. 2007 Oct 15; 13(20):6204-16. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, de Vere White RW, Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, de Vere White RW. PMID: 17947488.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    77. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm. 2007 Sep-Oct; 4(5):631-51. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS, Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. PMID: 17880166.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimals
    78. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007 Aug 01; 25(22):3296-301. Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED, Southwest Oncology Group , Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED, Southwest Oncology Group. PMID: 17664477.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    79. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World J Urol. 2007 Aug; 25(4):393-9. Nelson EC, Evans CP, Pan CX, Lara PN, Nelson EC, Evans CP, Pan CX, Lara PN. PMID: 17562051.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007 Feb 01; 13(3):953-7. Wang X, Zhang S, MacLennan GT, Eble JN, Lopez-Beltran A, Yang XJ, Pan CX, Zhou H, Montironi R, Cheng L, Wang X, Zhang S, MacLennan GT, Eble JN, Lopez-Beltran A, Yang XJ, Pan CX, Zhou H, Montironi R, Cheng L. PMID: 17289890.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    81. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006 Dec; 6(12):1707-13. Pan CX, Zhang H, Lara PN, Cheng L, Pan CX, Zhang H, Lara PN, Cheng L. PMID: 17181484.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    82. Implications of cancer stem cells in the treatment of cancer. Future Oncol. 2006 Dec; 2(6):723-31. Pan CX, Zhu W, Cheng L, Pan CX, Zhu W, Cheng L. PMID: 17155899.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    83. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol. 2005 Sep; 174(3):898-902. Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO, Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, Koch MO. PMID: 16093983.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    84. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. Oncology. 2005; 69(1):63-70. Pan CX, Loehrer P, Seitz D, Helft P, Juliar B, Ansari R, Pletcher W, Vinson J, Cheng L, Sweeney C, Pan CX, Loehrer P, Seitz D, Helft P, Juliar B, Ansari R, Pletcher W, Vinson J, Cheng L, Sweeney C. PMID: 16088234.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    85. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol. 2005 Aug; 18(8):1022-6. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO, Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. PMID: 15861213.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    86. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol. 2005 Jul; 36(7):718-23. Jones TD, Kernek KM, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Lin H, Pan CX, Tretiakova M, Baldridge LA, Cheng L, Jones TD, Kernek KM, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Lin H, Pan CX, Tretiakova M, Baldridge LA, Cheng L. PMID: 16084939.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    87. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005 May; 166(5):1533-9. Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, Lopez-Beltran A, Yang XJ, Koch MO, Zhang S, Pan CX, Baldridge LA, Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, Lopez-Beltran A, Yang XJ, Koch MO, Zhang S, Pan CX, Baldridge LA. PMID: 15855652; PMCID: PMC1606405.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    88. c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol. 2005 Mar; 18(3):320-3. Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Koch MO, Jones TD, Lin H, Nigro K, Papavero V, Tretiakova M, Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Koch MO, Jones TD, Lin H, Nigro K, Papavero V, Tretiakova M, Cheng L. PMID: 15502806.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    89. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004 Sep 01; 101(5):957-62. Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO, Eble JN, Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO, Eble JN. PMID: 15329903.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    90. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer. 2004 Jul 01; 101(1):83-9. Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, MacLennan GT, Cheng L, Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, MacLennan GT, Cheng L. PMID: 15221992.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    91. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer. 2004 Jul 01; 101(1):183-8. Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO, Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO. PMID: 15222005.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    92. Loss of 14-3-3sigma in prostate cancer and its precursors. Clin Cancer Res. 2004 May 01; 10(9):3064-8. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, Ulbright TM, Eble JN, Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, Koch MO, Ulbright TM, Eble JN. PMID: 15131044.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    93. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res. 2004 Feb 15; 10(4):1333-7. Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, Cheng L, Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, Cheng L. PMID: 14977833.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    94. Allelic loss of the active X chromosome during bladder carcinogenesis. Arch Pathol Lab Med. 2004 Feb; 128(2):187-90. Cheng L, MacLennan GT, Pan CX, Jones TD, Moore CR, Zhang S, Gu J, Patel NB, Kao C, Gardner TA, Cheng L, MacLennan GT, Pan CX, Jones TD, Moore CR, Zhang S, Gu J, Patel NB, Kao C, Gardner TA. PMID: 14736285.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    95. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol. 2003 Dec; 163(6):2271-6. Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L, Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA, Koch MO, Ulbright TM, Eble JN, Cheng L. PMID: 14633601; PMCID: PMC1892376.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimals
    96. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer. 2003 Nov 01; 98(9):1830-6. Paterson RF, Ulbright TM, MacLennan GT, Zhang S, Pan CX, Sweeney CJ, Moore CR, Foster RS, Koch MO, Eble JN, Cheng L, Paterson RF, Ulbright TM, MacLennan GT, Zhang S, Pan CX, Sweeney CJ, Moore CR, Foster RS, Koch MO, Eble JN, Cheng L. PMID: 14584063.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    97. A novel tumor-specific gene therapy for bladder cancer. Med Hypotheses. 1999 Aug; 53(2):130-5. Pan CX, Koeneman KS, Pan CX, Koeneman KS. PMID: 10532707.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    98. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol. 1998 Oct; 160(4):1533-9. Koeneman KS, Pan CX, Jin JK, Pyle JM, Flanigan RC, Shankey TV, Diaz MO, Koeneman KS, Pan CX, Jin JK, Pyle JM, Flanigan RC, Shankey TV, Diaz MO. PMID: 9751408.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    99. Changes in telomerase activity and telomere length during human T lymphocyte senescence. Exp Cell Res. 1997 Mar 15; 231(2):346-53. Pan C, Xue BH, Ellis TM, Peace DJ, Díaz MO, Pan C, Xue BH, Ellis TM, Peace DJ, Díaz MO. PMID: 9087176.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells